A
4.17
0.23 (5.84%)
| Previous Close | 3.94 |
| Open | 4.00 |
| Volume | 197,317 |
| Avg. Volume (3M) | 2,103,731 |
| Market Cap | 101,855,432 |
| Price / Sales | 8.11 |
| Price / Book | 0.640 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2025 |
| Diluted EPS (TTM) | -6.04 |
| Quarterly Revenue Growth (YOY) | -100.00% |
| Total Debt/Equity (MRQ) | 8.29% |
| Current Ratio (MRQ) | 13.93 |
| Operating Cash Flow (TTM) | -59.79 M |
| Levered Free Cash Flow (TTM) | -36.41 M |
| Return on Assets (TTM) | -33.29% |
| Return on Equity (TTM) | -68.14% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Artiva Biotherapeutics, Inc. | Bullish | Bearish |
AIStockmoo Score
-0.9
| Analyst Consensus | 3.0 |
| Insider Activity | -4.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -1.5 |
| Average | -0.90 |
|
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 19.99% |
| % Held by Institutions | 89.73% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 23.00 (Wedbush, 451.56%) | Buy |
| Median | 18.00 (331.66%) | |
| Low | 15.00 (HC Wainwright & Co., 259.71%) | Buy |
| Average | 18.67 (347.72%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 5.33 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 12 Nov 2025 | 15.00 (259.71%) | Buy | 3.98 |
| Needham | 17 Oct 2025 | 18.00 (331.65%) | Buy | 6.01 |
| Wedbush | 17 Oct 2025 | 23.00 (451.56%) | Buy | 6.01 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ASLAN FRED | - | 3.38 | -12,722 | -43,004 |
| BUSH JENNIFER | - | 3.25 | -3,055 | -9,929 |
| HORAN CHRISTOPHER | - | 3.25 | -1,899 | -6,172 |
| KRISHNAMOHAN NEHA | - | 3.25 | -3,490 | -11,343 |
| RAYMON HEATHER | - | 3.25 | -1,375 | -4,469 |
| Aggregate Net Quantity | -22,541 | |||
| Aggregate Net Value ($) | -74,916 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 3.29 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| ASLAN FRED | Officer | 17 Nov 2025 | Automatic sell (-) | 6,375 | 3.51 | 22,376 |
| ASLAN FRED | Officer | 15 Nov 2025 | Disposed (-) | 6,347 | 3.25 | 20,628 |
| KRISHNAMOHAN NEHA | Officer | 15 Nov 2025 | Disposed (-) | 3,490 | 3.25 | 11,343 |
| BUSH JENNIFER | Officer | 15 Nov 2025 | Disposed (-) | 3,055 | 3.25 | 9,929 |
| HORAN CHRISTOPHER | Officer | 15 Nov 2025 | Disposed (-) | 1,899 | 3.25 | 6,172 |
| RAYMON HEATHER | Officer | 15 Nov 2025 | Disposed (-) | 1,375 | 3.25 | 4,469 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |